Literature DB >> 15967124

Imaging multidrug resistance P-glycoprotein transport function using microPET with technetium-94m-sestamibi.

Heather M Bigott1, Julie L Prior, David R Piwnica-Worms, Michael J Welch.   

Abstract

The best characterized mechanism of multidrug resistance (MDR) in cancer involves the MDR1 efflux transporter P-glycoprotein (Pgp). The positron-emitting radiotracer hexakis(2-methoxyisobutylisonitrile)-(94m)Tc ((94m)Tc-MIBI) was synthesized and validated in cell transport studies as a substrate for MDR1 Pgp. In vivo small-scale PET imaging and biodistribution studies of mdr1a/1b (-/-) gene deleted and wild-type mice demonstrated the use of (94m)Tc-MIBI to detect Pgp function. The reversal effect of a Pgp modulator was shown in tissue distribution studies of KB 3-1 (Pgp-) and KB 8-5 (Pgp+) tumor-bearing nude mice. The current (94m)Tc-MIBI experiments parallel previous studies employing (99m)Tc-MIBI, showing essentially identical performance of the two technetium radiotracers and providing biological validation of (94m)Tc-MIBI for PET imaging of multidrug resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15967124

Source DB:  PubMed          Journal:  Mol Imaging        ISSN: 1535-3508            Impact factor:   4.488


  10 in total

1.  P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.

Authors:  William C Kreisl; Jeih-San Liow; Nobuyo Kimura; Nicholas Seneca; Sami S Zoghbi; Cheryl L Morse; Peter Herscovitch; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

2.  Loss of Par-1a/MARK3/C-TAK1 kinase leads to reduced adiposity, resistance to hepatic steatosis, and defective gluconeogenesis.

Authors:  Jochen K Lennerz; Jonathan B Hurov; Lynn S White; Katherine T Lewandowski; Julie L Prior; G James Planer; Robert W Gereau; David Piwnica-Worms; Robert E Schmidt; Helen Piwnica-Worms
Journal:  Mol Cell Biol       Date:  2010-08-23       Impact factor: 4.272

Review 3.  PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo.

Authors:  Severin Mairinger; Thomas Erker; Markus Muller; Oliver Langer
Journal:  Curr Drug Metab       Date:  2011-10       Impact factor: 3.731

4.  Assessing p-glycoprotein (Pgp) activity in vivo utilizing 68Ga-Schiff base complexes.

Authors:  Marco Fellner; Wolfgang Dillenburg; Hans-Georg Buchholz; Nicole Bausbacher; Mathias Schreckenberger; Franz Renz; Frank Rösch; Oliver Thews
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

Review 5.  Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.

Authors:  Stina Syvänen; Jonas Eriksson
Journal:  ACS Chem Neurosci       Date:  2012-12-04       Impact factor: 4.418

6.  Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function.

Authors:  Neva Lazarova; Sami S Zoghbi; Jinsoo Hong; Nicholas Seneca; Ed Tuan; Robert L Gladding; Jeih-San Liow; Andrew Taku; Robert B Innis; Victor W Pike
Journal:  J Med Chem       Date:  2008-09-11       Impact factor: 7.446

7.  P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys.

Authors:  Jeih-San Liow; William Kreisl; Sami S Zoghbi; Neva Lazarova; Nicholas Seneca; Robert L Gladding; Andrew Taku; Peter Herscovitch; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2008-12-17       Impact factor: 10.057

8.  Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein.

Authors:  Nicholas Seneca; Sami S Zoghbi; Jeih-San Liow; William Kreisl; Peter Herscovitch; Kimberly Jenko; Robert L Gladding; Andrew Taku; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2009-04-16       Impact factor: 10.057

9.  Molecular Imaging of P-glycoprotein in Chemoresistant Tumors Using a Dual-Modality PET/Fluorescence Probe.

Authors:  Mengzhe Wang; Chengqiong Mao; Hui Wang; Xueying Ling; Zhanhong Wu; Zibo Li; Xin Ming
Journal:  Mol Pharm       Date:  2017-08-30       Impact factor: 4.939

Review 10.  Imaging of multidrug resistance in cancer.

Authors:  S Dizdarevic; A M Peters
Journal:  Cancer Imaging       Date:  2011-03-01       Impact factor: 3.909

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.